4.7 • 789 Ratings
🗓️ 28 May 2021
⏱️ 35 minutes
🧾️ Download transcript
Click on a timestamp to play from that location
0:00.0 | Welcome to plenary session. |
0:07.0 | I'm Dr. Vinay Prasad. I'm an associate professor at the University of California, San Francisco. |
0:13.0 | My interests are medicine, hematology, oncology, and health policy, and that's what you're going to get on this podcast. |
0:23.7 | This week, we got a great episode in store for you. |
0:26.4 | We've got an interview, and I think you're going to really like this. |
0:30.0 | But first, a plug. |
0:33.3 | If you like this podcast, check out the new website, www. |
0:35.7 | www. plenary session podcast.com. |
0:39.5 | We've got show notes, we've got trial summaries, we've got everything you could want on the website. |
0:41.9 | Follow us on Twitter at plenary underscore session. |
0:45.2 | Write a review for us on the iTunes store. |
0:48.0 | And become a supporter for this podcast on Patreon. |
0:50.9 | Patreon backers get access to the slides for presentations I give on Plenary Session. |
0:55.1 | You also get a few bonus lectures. |
0:59.8 | And with that, let's start the show. |
1:03.0 | All right, I'm back in Plenary Session Video Edition, joined by Karin Tawaji, friend of the show. |
1:11.8 | She's been on before to do Journal Club with a fellow. |
1:15.1 | Those days are numbered because she'll no longer be a fellow for much longer. |
1:18.4 | Karin, it's a pleasure to speak with you again. |
1:20.9 | Thank you for having me. |
1:22.1 | I'm excited to be talking about the study today. |
1:25.2 | Me too, me too. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.